Arantal, an alternative therapy for osteoarthritis

Arantal in Osteoarthritis

bioXtract in vitro studies on curcumin show that curcumin:

• inhibits pro-inflammatory mediators (PGE₂, IL-6, IL-8) and acts on the pain of osteoarthritis,

• inhibits COX-2 but not COX-1 gene expression, and gives pain relief without unwanted gastro-intestinal side effects,

• inhibits the synthesis of NO and prevents cartilage breakdown in the joint.

Arantal Clinical Data

Arantal^® is delivered with a complete package of information, including bioXtract proprietary:

• Pre-clinical acute oral toxicity trial in rats showing no particular effect and classifying the product in the danger 5 category DL50 superior 5,000 mg/kg.

• Phase I clinical trial demonstrating bioavailability of Arantal^®'s active principals. (Complete report available on request)

• Phase II randomised, double-blind, multicenter clinical trial to evaluate the analgesic efficacy of Arantal^® in patients suffering from gonarthrosis, on a short term period (2 weeks).
  
  
  •  Arantal^® is an innovative food supplement offering a short term analgesic effect at a same level than acetaminophen.
    
    
  • Arantal^® is a safe product dedicated to the relief of pain in osteoarthritis, leading to a relief of pain between 30 to 35% in 2-weeks.

• Observational cohort study of Arantal^® on 1,077 patients suffering from osteoarthritis showing :
  
  
  • Arantal^® decreased pain with or without a concomitant treatment and that the effect observed depended on the duration of administration.
    
    
  • Arantal^® additive effect was to decrease the concomitant treatment intake (acetaminophen & NSAID). The dosage (2 caps in the morning + 2 caps in the afternoon) seemed optimal for most patients, without any relevant side effect reported (only nausea and bloating but infrequent & minor).

•  Clinical evaluation of the efficacy of Arantal^® during 6 months on 820 patients suffering from various joint painful osteoarthritis and showing:
  
  
  • significant reduction on pain (P<0.0001)
    
    
  • significant improvement of flexibility (P<0.0001)
    
    
  • significant decrease of initial medicamentations (painkillers, NSAIDs, chondroprotectives)
    
    
  • for 98% of the patients, satisfaction > previous treatment
    
    
  • excellent toleration

• Non-comparative exploratory study evaluating the clinical efficacy of Arantal^® on pain, side effects and effects on some biomarkers of osteoarthritis showing :
  
  

• significative decrease of cartilage degradation of biomarker Coll2-1
  
  
• 77% decrease of the inflammatory state of biomarker hsCRP
  
  
• significant improvement of global assessment of disease activity (p<0.005)

• Observational Study of Gout Attack on 54 patients showing :
  
  
  • fast improvement in acute pain within 24 to 48 hours for 90% of the patients
    
    
  • 65% of the patients continued therapy to prevent attacks with 2 caps/day during 3-6 months
    
    
  • 91% were completely satisfied